Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases

被引:214
作者
Beeton, C
Pennington, MW
Wulff, H
Singh, S
Nugent, D
Crossley, G
Khaytin, I
Calabresi, PA
Chen, CY
Gutman, GA
Chandy, KG
机构
[1] Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA
[2] Bachem Biosci Inc, King Of Prussia, PA USA
[3] Univ Calif Davis, Dept Med Pharmacol & Toxicol, Davis, CA 95616 USA
[4] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA
关键词
D O I
10.1124/mol.104.008193
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The voltage-gated Kv1.3 K+ channel is a novel target for immunomodulation of autoreactive effector memory T ( T EM) cells that play a major role in the pathogenesis of autoimmune diseases. We describe the characterization of the novel peptide ShK(L5) that contains L-phosphotyrosine linked via a nine-atom hydrophilic linker to the N terminus of the ShK peptide from the sea anemone Stichodactyla helianthus. ShK(L5) is a highly specific Kv1.3 blocker that exhibits 100-fold selectivity for Kv1.3 (K-d = 69 pM) over Kv1.1 and greater than 250-fold selectivity over all other channels tested. ShK(L5) suppresses the proliferation of human and rat TEM cells and inhibits interleukin-2 production at picomolar concentrations. Naive and central memory human T cells are initially 60-fold less sensitive than T EM cells to ShK( L5) and then become resistant to the peptide during activation by up-regulating the calcium-activated K(Ca)3.1 channel. ShK(L5) does not exhibit in vitro cytotoxicity on mammalian cell lines and is negative in the Ames test. It is stable in plasma and when administered once daily by subcutaneous injection (10 mu g/kg) attains "steady state" blood levels of similar to 300 pM. This regimen does not cause cardiac toxicity assessed by continuous EKG monitoring and does not alter clinical chemistry and hematological parameters after 2-week therapy. ShK(L5) prevents and treats experimental autoimmune encephalomyelitis and suppresses delayed type hypersensitivity in rats. ShK(L5) might prove useful for therapy of autoimmune disorders.
引用
收藏
页码:1369 / 1381
页数:13
相关论文
共 68 条
[11]   Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3 [J].
Butenschön, I ;
Möller, K ;
Hänsel, W .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (08) :1249-1256
[12]  
Camm AJ, 1996, CIRCULATION, V93, P1043
[13]  
CASTLE NA, 2000, Patent No. 6083986
[14]   K+ channels as targets for specific immunomodulation [J].
Chandy, KG ;
Wulff, H ;
Beeton, C ;
Pennington, M ;
Gutman, GA ;
Cahalan, MD .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (05) :280-289
[15]   VOLTAGE-GATED POTASSIUM CHANNELS ARE REQUIRED FOR HUMAN LYMPHOCYTE-T ACTIVATION [J].
CHANDY, KG ;
DECOURSEY, TE ;
CAHALAN, MD ;
MCLAUGHLIN, C ;
GUPTA, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 160 (02) :369-385
[16]   Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis [J].
Corcione, A ;
Casazza, S ;
Ferretti, E ;
Giunti, D ;
Zappia, E ;
Pistorio, A ;
Gambini, C ;
Mancardi, GL ;
Uccelli, A ;
Pistoia, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (30) :11064-11069
[17]   A potassium-channel toxin from the sea anemone Bunodosoma granulifera, an inhibitor for Kv1 channels - Revision of the amino acid sequence, disulfide-bridge assignment, chemical synthesis, and biological activity [J].
Cotton, J ;
Crest, M ;
Bouet, F ;
Alessandri, N ;
Gola, M ;
Forest, E ;
Karlsson, E ;
Castaneda, O ;
Harvey, AL ;
Vita, C ;
Menez, A .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 244 (01) :192-202
[18]   LARGE-SCALE PREPARATION OF MYELIN BASIC PROTEIN FROM CENTRAL NERVOUS-TISSUE OF SEVERAL MAMMALIAN SPECIES [J].
DEIBLER, GE ;
KIES, MW ;
MARTENSON, RE .
PREPARATIVE BIOCHEMISTRY, 1972, 2 (02) :139-+
[19]  
Ezawa K, 1997, ACTA MED OKAYAMA, V51, P25
[20]   Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3 [J].
Felix, JP ;
Bugianesi, RM ;
Schmalhofer, WA ;
Borris, R ;
Goetz, MA ;
Hensens, OD ;
Bao, JM ;
Kayser, F ;
Parsons, WH ;
Rupprecht, K ;
Garcia, ML ;
Kaczorowski, GJ ;
Slaughter, RS .
BIOCHEMISTRY, 1999, 38 (16) :4922-4930